Therapeutic potential of angiotensin II receptor antagonists

Bibliography

• JACKSON EK, GARRISON JC: Renin and angiotensin. In: The Pharmacological Basis of Therapeutics (Ninth edition). Drugs Affecting Renal and Cardiovascular Function. Wonsiewicz MJ, McCurdy P (Eds.) RR Donnelley and Sons Company, USA (1995)733–758.
   Google Scholar
• DUNCIA JV, CARINI DJ, CHIU AT etal.: The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med. Res. Rev (1992) 12:149–191.
   Google Scholar
• WHITEBREAD S, MELE M, KAMBER B, DE GASPARO M: Preliminary biochemial characterization of two angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. (1989) 163:284–291.
   PubMed Web of Science ®Google Scholar
• CHIU AT, CARINI DJ, JOHNSON AL et al.: Non-peptide angiotensin II receptor antagonists. II. Pharmacolocy of S-8308. Eur. Pharmacol. (1988) 157:13–21.
   Google Scholar
• SASAKI K, YAMANO Y, BARDHAN S et al.: Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature (1991) 351:230–233.
   PubMed Web of Science ®Google Scholar
• MUKOYAMA M, NAKAJIMA M, HORIUCHI M, SASAMURA H, PRATT RE, DZAU VJ: Expression cloning of Type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. _J. Biol. Chem. (1993) 268:24539–24542.
   PubMed Web of Science ®Google Scholar
• LORELL BH: Role of angiotensin ATi and AT2 receptors in cardiac hypertrophy and disease. Am. J. Cardiol. (1999) 83:H48–H52.
   Google Scholar
• BARRY WH, MATSUI H, BRIDGE JHB, SPITZER KW: Excitation-contraction coupling in ventricular myocytes: Effects of angiotensin II. Adv. Exp. Med. Biol. (1995) 382:31–39.
   PubMedGoogle Scholar
• KEM DC, JOHNSON El, CAPPONI AM et al.: Effects of angiotensin II on cytosolic free calcium in neonatal rat cardiomyocytes. Am. J. Physic] (1991) 261:C77–C85.
   Web of Science ®Google Scholar
• ACETO JF, BAKER KM: [Sari] angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am. I Physiol (1990) 258:H806–H813.
   PubMed Web of Science ®Google Scholar
• NAFTILAN AJ, PRATT RE, ELDRIDGE CS, LIN HL, DZAU VJ: Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension v(1989) 13:706–711.
   PubMed Web of Science ®Google Scholar
• GEISTERFER AAT, PEACH MJ, OWENSGK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. (1988) 62:749–756.
   PubMed Web of Science ®Google Scholar
• KHAIRALLAH PA, KANABUS J: Angiotensin and myocardial protein synthesis. Perspect. Cardovasc. Res. (1983) 8:337–347.
   Google Scholar
• LING S, DAI A, MA YH et al.: Matrix-dependent gene expression of Egr-1 and PDGF A regulate angiotensin II-induced proliferation in human vascular smooth muscle cells. Hypertension (1999) 34:1141–1146.
   PubMed Web of Science ®Google Scholar
• REID IA: Interaction between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am. j Physic] (1992) 262:E763–E778.
   PubMed Web of Science ®Google Scholar
• LIU JL, ZUCKER IH: Regulation of sympathetic nerve activity in heart failure. A role for nitric oxide and angiotensin II. Circ. Res. (1999) 84:417–423.
   Google Scholar
• LEENEN FHH, HUANG BS, YU H, YUAN B: Brain ouabain' mediates sympathetic hyperactivity in congestive heart failure. Circ. Res. (1995) 77:993–1000.
   PubMed Web of Science ®Google Scholar
• HUANG BS, LEENEN FHH: Brain renin-angiotensin system and ouabain-induced sympathetic hyperactivity and hypertension in Wistar rats. Hypertension (1999) 34:107–112.
   PubMed Web of Science ®Google Scholar
• GOODFRIEND TL, ELLIOTT ME, CATT KJ: Angiotensin receptors and their antagonists. N Engl. I Med. (1996) 334:1649–1654.
   PubMed Web of Science ®Google Scholar
• KIMURA T, TODA N, NODA Y, OKAMURA T: Mechanisms of relaxation induced by angiotensin II in isolated canine and human uterine arteries. j Cardiovasc. Pharmacal. (2001) 37:585–595.
   PubMed Web of Science ®Google Scholar
• LEMAY J, HOU Y, DEBLOIS D: Evidence that nitric oxide regulates AT1-receptor agonist and antagonist efficacy in rat injured carotid artery. I Cardiovasc. Pharmacal. (2000) 35:693–699.
   PubMed Web of Science ®Google Scholar
• MARSEN TA, SUKAU G, POLLOK M, BALDAMUS CA: Enalapril and losartan augment endogenous nitric oxide release in Takayasu's arteritis - A case report. Angiology (2000) 51:69–75.
   PubMed Web of Science ®Google Scholar
• KALLIOVALKAMA J, JOLMA P, TOLVANEN JP et al.: Arterial function in nitric oxide-deficient hypertension: Influence of long-term angiotensin II receptor antagonism. Cardiovasc. Res. (1999) 42:773–782.
   PubMed Web of Science ®Google Scholar
• SEYEDI N, XU XB, NASJLETTI et al.: Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension (1995) 26:164–170.
   PubMed Web of Science ®Google Scholar
• SIRAGY HM, CAREY RM: The Subtype 2 (AT2) Angiotensin Receptor Mediates Renal Production of Nitric Oxide in Conscious Rats. j OM. Invest. (1997) 100:264–269.
   PubMed Web of Science ®Google Scholar
• GOHLKE P, PEES C, UNGER T: AT2 Receptor Stimulation Increases Aortic Cyclic GMP in SHRSP by a Kinin-Dependent Mechanism. Hypertension (1998) 31:349–355.
   PubMed Web of Science ®Google Scholar
• TSUTSUMI Y, MATSUBARA H, MASAKI H et al.: Angiotensin II Type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. j OM. Invest. (1999) 104:925–935.
   PubMed Web of Science ®Google Scholar
• MORRELI NW UPTON PD, KOTECHA S et al.: Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via ATI. receptors. Am. I Physial. (1999) 277:L440–L448.
   Google Scholar
• SCHNEE JM, HSUEH WA: Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc. Res. (2000) 46:264–268.
   PubMed Web of Science ®Google Scholar
• BERK BC, HAENDELER J, SOTTILE J: Angiotensin II, atherosclerosis, and aortic aneurysms. I OM. Invest. (2000) 105:1525–1526.
   Google Scholar
• TUMMALA PE, CHEN XL, SUNDELL CL et al.: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature. A potential link between the renin-angiotensin system and atherosclerosis. Circulation (1999) 100:1223–1229.
   Google Scholar
• FORD CM, LI S, PICKERING JG: Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the ATi receptor, transforming growth factor-I3, and tyrosine phosphorylation. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1843–1851.
   Google Scholar
• BERK BC, CORSON MA: Angiotensin II signal transduction in vascular smooth muscle. Role of tyrosine kinases. Circ. Res. (1997) 80:607–616.
   PubMed Web of Science ®Google Scholar
• KAJSTURA J, CIGOLA E, MALHOTRA A et al.: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. I Mai Cell. Cardial. (1997) 29:859–870.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, FUSHIMI K, KOUCHI H et al.: Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation (1998) 98:794–799.
   PubMed Web of Science ®Google Scholar
• ZHANG H, SCHMEIPER A, GARLICHS CD et al.: Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc. Res. (1999) 44:215–222.
   PubMed Web of Science ®Google Scholar
• FUKAI T, SIEGFRIED MR, USHIO-FUKAI M, GRIENDLING HARRISON DG: Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ. Res. (1999) 85:23–28.
   PubMed Web of Science ®Google Scholar
• PASTORE L, TESSITORE A, MARTINOTTI S et al.: Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation (1999) 100: 1646-1652.
   Google Scholar
• LANG D, MOSFER SI, SHAKESBY A, DONALDSON F, LEWIS MJ: Coronary microvascular endothelial cell redox state in left ventricular hypertrophy. The role of angiotensin II. Circ. Res. (2000) 86:463–469.
   Web of Science ®Google Scholar
• SAINO A, POMIDOSSI G, PERONDI R,MORGANTI A, TUROLO L, MANCIA G: Modulation of sympathetic coronary vasoconstriction by cardiac renin-angiotensin system in human coronary heart disease. Circulation (2000) 101:2277–2283.
   PubMed Web of Science ®Google Scholar
• REISS K, CAPASSO JM, HUANG HE, MEGGS LG, LIP, AN VERSA P: ANG II receptors, c-myc, and c-jun in myocytes after myocardial infarction and ventricular failure. Am. I Physial. (1993) 264:H760–H769.
   PubMed Web of Science ®Google Scholar
• URATA H, HEALY B, STEWART RW, BUMPUS FM, HUSAIN A: Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. (1990) 66:883–890.
   PubMed Web of Science ®Google Scholar
• ZISMAN LS, ABRAHAM WT, MEIXELL GE et al.: Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. OM. Invest. (1995) 95:1490–1498.
   Google Scholar
• PARADIS P, DALI-YOUCEF N, PARADIS FW, THIBAULT G, NEMER M: Overexpression of angiotensin II Type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Nati Acad. Sci. USA (2000) 97:931–936.
   PubMed Web of Science ®Google Scholar
• MATSUBARA H: Pathophysiological role of angiotensin II Type 2 receptor in cardiovascular and renal diseases. Circ. Res. (1998) 83:1182–1191.
   PubMed Web of Science ®Google Scholar
• DAUGHERTY A, MANNING MW, CASSIS LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. I Chit Invest. (2000) 105:1605–1612.
   PubMed Web of Science ®Google Scholar
• KRANZHOFER R, SCHMIDT J, PFEIFFER CAH, HAGL S, LIBBY P, KLIBLER W: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1623–1629.
   PubMed Web of Science ®Google Scholar
• LI DY, ZHANG YC, PHILIPS MI, SAWAMURA T, MEHTA JL: Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II Type 1 receptor activation. Circ. Res. (1999) 84:1043–1049.
   PubMed Web of Science ®Google Scholar
• TUMMALA PE, CHEN XL, SUNDELL CL eta].: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature. A potential link between the renin-angiotensin system and atherosclerosis. Circulation (1999) 100:1223–1229.
   Google Scholar
• WARNHOLTZ A, NICKENIG G, SCHULZ E et al.: Increased NADH-Oxidase-Mediated Superoxide Production in the Early Stages of Atherosclerosis. Evidence for Involvement of the Renin-Angiotensin System. Circulation (1999) 99:2027–2033.
   Google Scholar
• GRIENDLING KK, MINIERI CA, OLLERENSHAW R, ALEXANDER W: Angiotensin II Stimulates NADH and NADPH Oxidase Activity in Cultured Vascular Smooth Muscle Cells. Circ. Res. (1994) 74:1141–1148.
   PubMed Web of Science ®Google Scholar
• SOHN HY, RAFF U, HOFFMANN A et al.: Differential role of angiotension II receptor on endothelial superoxide formation. Br j Pharmacol (2000) 131:667–672.
   PubMed Web of Science ®Google Scholar
• GOODFIELD NER, NEWBY DE, LUDLAM CA, FLAPAN AD: Effects of acute angiotensin II Type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation (1999) 99:2983–2985.
   PubMed Web of Science ®Google Scholar
• NAKAMURA S, NAKAMURA I, MA L, VAUGHAN DE, FOGO AB: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin Type 1 receptor in vivo. Kidney Int. (2000) 58:251–259.
   PubMed Web of Science ®Google Scholar
• REINHART GA, LOHMEIER TE, HORD EC Jr: Hypertension induced by chronic renal adrenergic stimulation is angiotensin dependent. Hypertension (1995) 25:940–949.
   PubMed Web of Science ®Google Scholar
• ESLER MD, NESTEL PJ: Renin and sympathetic nervous system responsiveness to adrenergic stimuli in essential hypertension. Am. j Cardiol (1973) 32:643–649.
   PubMed Web of Science ®Google Scholar
• BLUMENFELD JD, SEALEY JE, MANN SJ et al.: Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am. J. Hypertens. (1999) 12:451–459.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN BG, SYBERTZ EJ, WONG PC: Interaction between sympathetic and renin-angiotensin system. Hypertens. (1984) 2:581–587.
   Google Scholar
• ANDREWS CO, CRIM JW, HARTLE DK: Angiotensin II binding in area postrema and nucleus tractus solitarius of SHR and WKY rats. Brain Res. Bull. (1993) 32:419–424.
   PubMed Web of Science ®Google Scholar
• WONG PC, BERNARD R, TIMMERMANS PBMWM: Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension (1992) 19:663–667.
   PubMed Web of Science ®Google Scholar
• NEW RB, SAMPSON AC, KING MK et al.: Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: Effects on left ventricular performance. Circulation (2000) 102:1447–1453.
   PubMed Web of Science ®Google Scholar
• MOREAU P, D'USCIO LV, SHAW S, TAKASE H, BARTON M, LOSCHER TF: Angiotensin II increases tissue endothelin and induces vascular hypertrophy. Reversal by ETA-receptor antagonist. Circulation (1997) 96:1593–1597.
   PubMed Web of Science ®Google Scholar
• MEGGS LG, COUPET J, HUANG H etal.: Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ. Res. (1993) 72:1149–1162.
   Google Scholar
• CHENG CP, SUZUKI M, OHTE N, OHNO M, WANG ZM, LITTLE WC: Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ. Res. (1996) 78:880–892.
   PubMed Web of Science ®Google Scholar
• ASANO K, DUTCHER DL, PORT JD et al.: Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation (1997) 95:1193–1200.
   PubMed Web of Science ®Google Scholar
• HAYWOOD GA, GULLESTAD L, KATSUYA T et al: ATi and AT2 angiotensin receptor gene expression in human heart failure. Circulation (1997) 95:1201–1206.
   PubMed Web of Science ®Google Scholar
• TIMMERMANS PB. Angiotensin II receptor antagonists: An emerging new class of cardiovascular therapeutics. Hypertens. Res. (1999) 22:147–153.
   PubMed Web of Science ®Google Scholar
• LIU YH, YANG XP, SHAROV VG et al: Effects of angiotensin-converting enzyme inhibitors and angiotensin II Type 1 receptor antagonists in rats with heart failure. j Clin. Invest. (1997) 99:1926–1935.
   PubMed Web of Science ®Google Scholar
• SUDHIR K, MACGREGOR JS, GUPTA M, BARBANT SD, REDBER GR: Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studdies. Circulation (1993) 87:931–938.
   Google Scholar
• HORNIG B, KOHLER C, DREXLER H: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation (1997) 95:1115–1118.
   PubMed Web of Science ®Google Scholar
• BROWN NJ, NADEAU JH, VAUGHAN DE: Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb. Haemost. (1997) 77:522–525.
   PubMed Web of Science ®Google Scholar
• GOHLKE P, LINZ W, SCHOLKENS BA,WIEMER G, UNGER T: Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension (1996) 28:397–402.
   PubMed Web of Science ®Google Scholar
• TAKEDA K, FUJITA H, NAKAMURA K et al.: Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats. Blood Press. (1994) 5(Suppl.):94–98.
   Google Scholar
• KAGOSHIMA T, MASUDA J, SUTANI T et al.: Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. Blood Press (1994) 5(Suppl.):89–93.
   Google Scholar
• BRUCKSCHLEGEL G, HOLMER SR, JANDELEIT K et al.: Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension (1995) 25:250–259.
   PubMed Web of Science ®Google Scholar
• RAYA TE, FONKEN SJ, LEE RW et al: Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am. Hypertens. (1991) 4:334S–340S.
   Google Scholar
• SCHIEFFER B, WIRGER A, MEYBRUNN M et al: Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II Type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation (1994) 89:2273–2282.
   PubMed Web of Science ®Google Scholar
• KOHYA T, YOKOSHIKI H, TOHSE N et al.: Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ. Res. (1995) 76:892–899.
   Google Scholar
• KORSGAARD N, AALKJAER C, HEAGERTY AM, IZZARD AS, MULVANY MJ: Histology of subcutaneous small arteries from patients with essential hypertension. Hypertension (1993) 22:523–526.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, DENG LY: Relationship between small-artery structure and systolic, diastolic and pulse pressure in essential hypertension. J. Hyperterts. (1999) 17:381–387.
   PubMed Web of Science ®Google Scholar
• LI JS, SHARIFI AM, SCHIFFRIN EL: Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR. j Cardiovasc. Pharmacol (1997) 30:75–83.
   PubMed Web of Science ®Google Scholar
• LI JS, TOUYZ RM, SCHIFFRIN EL: Effects of ATi and AT2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension (1998) 31:487–492.
   PubMed Web of Science ®Google Scholar
• STRAWN WB, CHAPPELL MC, DEAN RH, KIVLIGHN S, FERRARIO CM: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation (2000) 101:1586–1593.
   PubMed Web of Science ®Google Scholar
• HAYEK T, AVIRAM M, HEINRICH R, SAKHNINI E, KEIDAR S: Losartan inhibits cellular uptake of oxidized LDL by monocyte-macrophages from hypercholesterolemic patients. Biochem. Biophys. Res. Commun. (2000) 273:417–420.
   PubMed Web of Science ®Google Scholar
• DE LAS HERAS N, ARAGONCILLO P, MASEO R et al: AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension (1999) 34:969–975.
   PubMed Web of Science ®Google Scholar
• GUERRA-CUESTA JI, MONTON M, RODRIGUEZ-FEO JA et al: Effect of losartan on human platelet activation. Hypertens. (1999) 17:447–452.
   Web of Science ®Google Scholar
• MONTON M, JIMENEZ A, NUNEZ A et al.: Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. j Cardiovasc. Pharmacol (2000) 35:906–913.
   PubMed Web of Science ®Google Scholar
• LI P, FUKUHARA M, DIZ DI, FERRARIO CM, BROSNIHAN KB: Novel angiotensin II ATi receptor antagonist irbesartan prevents thromboxane kinduced vasoconstriction in canine coronary arteries and human platelet aggregation. j Pharmacol Exp. Ther. (2000) 292:238–246.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, DENG LY, LAROCHELLE P: Effect of a I3-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension (1994) 23:83–91.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, DENG LY, LAROCHELLE P: Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a P-blocker. Am. I Hypertens. (1995) 8:229–236.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, PARK JB, INTENGAN HD, TOUYZ RIVI: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation (2000) 101:1653–1659.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, HERLITZ H, AURELL M, HANSSON L: Reversal of Cardiovascular Structural Changes When Treating Essential Hypertension. The importance of the Renin-Angiotensin-Aldosterone System. Am. J. Hypertens (1992) 5:900–911.
   Google Scholar
• BERRY C, HAMILTON CA, BROSNAN MJ etal.: Investigation into the sources of superoxide in human blood vessels: Angiotensin II increases superoxide production in human internal mammary arteries. Circulation (2000) 101:2206–2212.
   Google Scholar
• ANDERSON TJ, ELSTEIN E, HABER H, CHARBONNEAU F: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). Am. Coll. Cardiol (2000) 35:67–70.
   PubMedGoogle Scholar
• PRASAD A, TUPAS-HABIB T, SCHENKE WH et al.: Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation (2000) 101:2349–2354.
   PubMed Web of Science ®Google Scholar
• HORNIG B, LANDMESSER U, KOHLER C et al: Comparative effect of ACE inhibition and angiotensin II Type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation (2001) 103:799–805.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl. I Med. (1993) 329:1456–1462.
   PubMed Web of Science ®Google Scholar
• MUIRHEAD N, FEAGAN BF, MAHON Jet al.: The effects of valsartan and captopril on reducing microalbuminuria in patients with Type 2 diabetes mellitus: A placebo-controlled trial. Curr. Ther. Res. (1999) 60:650–660.
   Google Scholar
• MOGENSEN CE, NELDAM S, TIKKANEN I et al., for the CALM study group: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ(2000) 321:1440–1444.
   PubMed Web of Science ®Google Scholar
• Reduction of Endpoints in Non-insulin dependent diabetes mellitus with Angiotensin-II Antagonist Losartan (RENAAL); presented at the 16th Annual Scientific Meeting of the American Society of Hypertension 2001, San Francisco, California (press release).
   Google Scholar
• Program for Irbesartan Mortality and morbidity Evaluations; presented at the 16th Annual Scientific Meeting of the American Society of Hypertension 2001, San Francisco, California (press release). loz. VAUGHAN DE, ROULEAU JL, RIDKER PM, ARNOLD JM, MENAPACE FJ, PFEFFER MA: Effects of ramipril on plasma flbrinolytic balance in patients with acute anterior myocardial infarction. HEART study investigators. Circulation (1997) 96:442–447.
   Google Scholar
• ERDEM Y, USALAN C, HAZNEDAROGLU IC et al: Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am. I Hypertens. (1999) 11:1071–1076.
   Google Scholar
• CREAGER MA, CREAGER SJ: Arterial baroreflex regulation of blood pressure in patients with congestive heart failure. I Am. Coll. Cardiol (1994) 23:401–405.
   PubMed Web of Science ®Google Scholar
• OSTERZIEL KJ, HANLEIN D, WILLENBROCK R, EICHHORN C, LUFT F, DIETZ R: Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure. Br. Heart J. (1995) 73:517–522.
   PubMedGoogle Scholar
• YEE KM, STRUTHERS AD: Endogenous angiotensin II and baroreceptor dysfunction: A comparative study of losartan and enalapril in man. Br. j Chit Pharmacol (1998) 46:583–588.
   PubMed Web of Science ®Google Scholar
• LIGTENBERG G, BLANKESTIJN PJ, OEY PL et al: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl. I Med. (1999) 340:1321–1328.
   PubMed Web of Science ®Google Scholar
• RONGEN GA, BROOKS SC, ANDO S, DAJANI HR, ABRAMSON BL, FLORAS JS: Neural and hypotensive effects of angiotensin II receptor blockade. Hypertension (1998) 31:378-383. los. K-LAFLAMME A, OSTER L, 1699 CARDINAL R, DE CHAMPLAIN J: Effects of renin-angiotensin blockade on sympathetic reactivity and $-adrenergic pathway in the spontaneously hypertensive rat. Hypertension (1997) 30\(Part 1):278–287.
   Google Scholar
• CROZIER I, IKRAM H, AWAN N et al.: Losartan in heart failure. Hemodynamic effects and tolerability. Circulation (1995) 91:691–697.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-GARCIA JL, PAULE A, DOMINGUEZ J, GARCIA-ESCRIBANO JR, VAZQUEZ M: Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure. IrM j Cardiol (1999) 70:293–301.
   PubMed Web of Science ®Google Scholar
• TSUTAMOTO T, WADA A, MAEDA K et al.: Angiotensin II Type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. j. Am. Coll. Cardiol. (2000) 35:714–721.
   PubMed Web of Science ®Google Scholar
• HANSSON L, LINDHOLM LH, EKBOM T et al.:Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet (1999) 354: 1751-1756.
   Google Scholar
• ADLER AI, STRATTON IM, NEIL HAW et al.: Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 36): prospective observational study. EMI-(2000) 321:412–419.
   Google Scholar
• HANSSON L, ZANCHETTI A, CARRUTHERS SG et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 351:1755–1762.
   PubMed Web of Science ®Google Scholar
• HANSSON L, LINDHOLM LH, NISKANEN L et al.:Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (1999) 353:611–616.
   PubMed Web of Science ®Google Scholar
• THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of an angiotension-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Ere. j Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• WEBER MA: Comparison of Type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. I Hyperterts. (1997) 15(Suppl):531–536.
   Google Scholar
• DAHLOF B. Left Ventricular Hypertrophy and Angiotensin II Antagonists. Am. j. Hyperterts. (2001) 14:174–182.
   PubMed Web of Science ®Google Scholar
• CHAPUT AJ: Persistency with angiotensin receptor blockers (ARB) versus other antihypertensives (AHT) using the Saskatchewan database. Can. j. Cardiol (2000) 16(Suppl.):194F.
   Google Scholar
• DICKSTEIN K, CHANG P, WILLENHEIMER R, HAUNSO S, REMES J, HALL C, KJEKSHUS J: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. j Am. Coll. Cardiol (1995) 26:438–445.
   PubMed Web of Science ®Google Scholar
• LANG RM, ELKAYAM U, YELLIN LG et al.: on behalf of the Losartan Pilot Exercise Study Investigators: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J. Am. Coll. Cardiol (1997) 30:983–991.
   PubMed Web of Science ®Google Scholar
• KLINGER G, JARAMILLO N, IKRAM H et al: Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. _J. Am. Coll. Cardiol (1997) 29(Suppl. A):205A.
   Google Scholar
• GRANGER CB, ERTL G, KUCH J et al: Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart J. (2000) 139:609–617.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SS, DICKSTEIN K, FLECK E et al: Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation (1993) 88:1602–1609.
   PubMed Web of Science ®Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al, on behalf of ELITE study investigators: Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R etal.: on behalf of the ELITE II investigators: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582–1587.
   Google Scholar
• THE RESOLVD PILOT STUDY INVESTIGATORS: Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation (1999) 100:1056–1064.
   PubMed Web of Science ®Google Scholar
• JORDE UP, ENNEZAT PV, LISKER J et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation (2000) 101:844–846.
   PubMed Web of Science ®Google Scholar
• HAMROFF G, KATZ SD, MANCINI D et al.: Addition of angiotensin II recpetor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 99:990–992.
   PubMed Web of Science ®Google Scholar
• GUAZZI M, PALERMO P, PONTONE G, SUSINI F, AGOSTONI P: Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am. Cardiol (1999) 84:1038–1043.
   PubMed Web of Science ®Google Scholar
• BARUCH L, ANAND I, COHEN IS, ZIESCHE S, JUDD D, COHN JN: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) study group. Circulation (1999) 99:2658–2664.
   PubMed Web of Science ®Google Scholar
• COHN JN, TOGNONI G, GLAZER R, SPORMANN D: Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur. j. Heart Fail. (2000) 2:439–446.
   PubMed Web of Science ®Google Scholar
• Results of the Valsartan Heart Failure Trial; presented at the 40th Annual Scientific Meeting of the American Heart Association (2000), New Orleans, Louisianna (press release).
   Google Scholar
• BRISTOW MR, ZEUS R: Baseline and three month change in systemic venous norepinephrine as predictors of clinical outcomes in the BEST trial investigators. j. Am. Coll. Cardiol (2001) 37:183A.
   PubMed Web of Science ®Google Scholar
• MANN J, JULIUS S, FOR THE VALUE TRIAL GROUP: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure (1998) 7:176–183.
   PubMedGoogle Scholar
• DAHLOF B, DEVEREUX R, DE FAIRE U et al: The losartan intervention for endpoint reduction (LIFE) in hypertension study. Rationale, design, and methods. Am. Hypertens. (1997) 10:705–713.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, DEVEREUX RB, JULIUS S et al.: Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE study. Hypertension (1998) 32:989–997.
   PubMed Web of Science ®Google Scholar
• DICKSTEIN K, KJEKSHUS J, FOR THE OPTIMAAL STUDY GROUP: Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL trial design. Am. J. Cardiol (1999) 83:477–481.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, MCMURRAY J, LEIZOROVICZ A et al., for the VALIANT Investigators: Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design. Am. Heart j (2000) 140:727–734.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, PFEFFER M, GRANGER C et al: Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM): Rationale and design. Charm-Program Investigators. j Card. Fah. (1999) 5:276–282.
   PubMedGoogle Scholar
• BURNIER M, BRUNNER HR: Angiotensin II receptor antagonists in hypertension. Kidney Intern. (1998). 54\(Suppl. 68):S107–S111.
   Google Scholar
• BURNIER M. Angiotensin II Type 1 receptor blockers. Circulation (2001) 103:904–912.
   PubMed Web of Science ®Google Scholar
• JOHNSTON CI, RISVANIS J: Preclinical pharmacology of angiotensin II receptor antagonists. Update and outstanding issues. Am. J. Hypertens. (1997) 10:306S–310S.
   Google Scholar
• FIERENS FLP, VANDERHEYDEN PML, DE BACKER JP et al.: Insurmountable angiotensin ATi receptor antagonists : the role of tight antagonist binding. Eur. Pharmacol. (1999) 372:199–206.
   Google Scholar